ArticleESMO open2026
Pattern and quality of care for rare head and neck cancers treated in expert centres: the experience of the registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN).
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRare head and neck cancers (HNCs), including sinonasal cancers (SNC), nasopharyngeal cancers (NPC), and salivary gland cancers (SGC), are biologically diverse and infrequent, resulting in limited high-quality evidence to guide clinical management. This study evaluated real-world patterns and quality of care in Italy for these rare HNCs within the European Reference Network for Rare Adult Solid Cancers (EURACAN) registry. PATIENTS AND
methodsData from 795 adult patients diagnosed or managed at Italian expert centres between 2018 and 2024 with rare HNCs (152 SNC, 201 NPC, and 442 SGC) were analysed. Key indicators assessed included diagnostic completeness, adherence to European clinical practice guidelines, and timeliness of treatment. Analyses were stratified by tumour type and care setting.
resultsMost patients presented with locally advanced disease (70% SNC, 74% NPC, and 50% SGC). Epstein-Barr virus testing was carried out in 80% of NPC cases. Treatment approaches were heterogeneous, especially for SNC, where multimodal therapy varied widely. Guidelines deviations were common: ∼50% of patients with localised SGC and 67% of those with localised NPC did not receive guideline-recommended treatments. Treatment delays were frequent, with 48%-77% of patients failing to initiate treatment within recommended timeframes. These delays were predominantly associated with interhospital referral pathways and were more pronounced in patients requiring multimodal treatments.
conclusionsThis registry-based analysis reveals substantial variability in treatment strategies and frequent treatment delays for rare HNCs, even within expert centres. Improving referral coordination, adherence to guidelines, and timely initiation of treatment remain critical. The EURACAN registry represents a valuable tool for benchmarking and enhancing care quality, supporting evidence-informed treatment decisions for these rare and complex cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.